Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate HCl Clear all
Recruiting No phase listed Observational

WAKIX® (Pitolisant) Pregnancy Registry

NCT05536011
View directory record Official record
Conditions
Pregnancy Related, Narcolepsy
Interventions
Pitolisant, Comparator Products
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
Female only
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Commonly Used Medications on Mood and Choice

NCT03652740
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Methylphenidate, Nicotine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

NCT02638168
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Interventions
Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 17, 2026, 6:03 PM EDT
Recruiting Phase 2 Interventional

The Role of Brain Dopamine in Chronic Pain

NCT05285683
View directory record Official record
Conditions
Chronic Pain
Interventions
Methylphenidate, carbidopa-levodopa, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

NCT00972985
View directory record Official record
Conditions
Healthy
Interventions
modafinil, methylphenidate, lorazepam, placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

NCT00061087
View directory record Official record
Conditions
ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions
Methylphenidate, Bupropion, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 17, 2026, 6:03 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 17, 2026, 6:03 PM EDT
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

NCT01377662
View directory record Official record
Conditions
Methamphetamine Dependence, Cocaine Dependence
Interventions
OND-PR002 and MPh-IR, Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Drug · Other
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02225106
View directory record Official record
Conditions
Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Results available

General Anesthesia Emergence Induced by Methylphenidate

NCT02327195
View directory record Official record
Conditions
Delayed Emergence From Anesthesia
Interventions
Methylphenidate HCl, Placebo
Drug
Lead sponsor
Nicoleta Stoicea
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

NCT00602290
View directory record Official record
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Not applicable Interventional Results available

Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)

NCT00453921
View directory record Official record
Conditions
Brain Injury
Interventions
Methylphenidate, Memory and Attention Training, Placebo as both treatments
Drug · Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Indianapolis, Indiana • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 17, 2026, 6:03 PM EDT
Active, not recruiting Phase 4 Interventional

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

NCT05469386
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 17, 2026, 6:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT03525873
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Methylphenidate, Physical Activity, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

NCT05474846
View directory record Official record
Conditions
Sleep, Fatigue, Anxiety, Cancer, Depression
Interventions
Melatonin, Placebo for Melatonin, Methylphenidate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 6:03 PM EDT
Terminated Not applicable Interventional Results available

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658
View directory record Official record
Conditions
ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute, L1, Lymphoblastic Leukemia, Acute, L2, Lymphoblastic Lymphoma, Lymphocytic Leukemia, Acute, Lymphocytic Leukemia, L1, Lymphocytic Leukemia, L2, Brain Tumors, Cancer of the Brain, Cancer of Brain, Malignant Primary Brain Tumors, Brain Neoplasms, Malignant
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 17, 2026, 6:03 PM EDT
Withdrawn Phase 4 Interventional

Adaptive Response to Intervention (RTI) for Students With ADHD

NCT03511976
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 4 Interventional

Treatment of Patients With Alcoholism and Attention Deficit Disorder

NCT00261872
View directory record Official record
Conditions
Alcoholism, Attention Deficit Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

Cocaine-Methylphendidate Interaction Study - 4

NCT00015067
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 6:03 PM EDT
Completed No phase listed Observational

Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate

NCT00341029
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 6:03 PM EDT